Zobrazeno 1 - 10
of 482
pro vyhledávání: ''
Autor:
David M. O'Malley, Maryna Neffa, Bradley J. Monk, Tamar Melkadze, Marilyn Huang, Anna Kryzhanivska, Iurie Bulat, Tarek M. Meniawy, Andrea Bagameri, Edward W. Wang, Bernard Doger de Speville Uribe, Roberto Hegg, Waldo Ortuzar Feliu, Marek Ancukiewicz, Iwona Lugowska
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 40(7)
PURPOSE Balstilimab (antiprogrammed death-1) and zalifrelimab (anticytotoxic T-lymphocyte–associated antigen-4) are two new checkpoint inhibitors emerging as promising investigational agents for the treatment of advanced cervical cancer. This phase
Autor:
György Bodoky, Dung Thai, Manish A. Shah, Alexander Starodub, Johanna C. Bendell, Joyce He, David Cunningham, Jaffer A. Ajani, Zev A. Wainberg, Pankaj Bhargava, Desmond Yip
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol 39, iss 9
PURPOSE Andecaliximab (ADX) is a monoclonal antibody that inhibits matrix metalloproteinase 9, an extracellular enzyme involved in matrix remodeling, tumor growth, and metastases. A phase I and Ib study of modified oxaliplatin, leucovorin, and fluoro
Autor:
Martin R. Weiser, Ajaratu Keshinro, Zsofia K. Stadler, William C. Chapman, J. Joshua Smith, Emmanouil P. Pappou, Efsevia Vakiani, Iris H Wei, Tsuyoshi Konishi, Garrett M. Nash, Andrea Cercek, Maria Widmar, Philip B. Paty, Julio Garcia-Aguilar, Yoshifumi Shimada, Meier Hsu, Mithat Gonen, Iván González, Philip S. Bauer, Jinru Shia, Leonard B. Saltz, Neil H. Segal, Deepak Lingam, Rona Yaeger, Matthew G. Mutch, Deyali Chatterjee, Anna M. Varghese
Publikováno v:
J Clin Oncol
PURPOSE Clinical calculators and nomograms have been endorsed by the American Joint Committee on Cancer (AJCC), as they provide the most individualized and accurate estimate of patient outcome. Using molecular and clinicopathologic variables, a third
Autor:
Stephen J. Forman, Ellen K Chang, Kelly Peng, Saro H. Armenian, LiYing Cai, Ryotaro Nakamura, Aleksi Iukuridze, Dayana Chanson, Jennifer Berano Teh, F. Lennie Wong
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 39(8)
PURPOSE To examine the incidence and risk factors for de novo atrial fibrillation (AF) after allogeneic hematopoietic cell transplantation (HCT) and to describe the impact of AF on HCT-related outcomes. METHODS A retrospective cohort study design was
Autor:
Gina M. Vaccaro, Yung-Jue Bang, Julien Taieb, Zev A. Wainberg, Markus Moehler, Matthew R. Silver, Janet Hong, Arinilda Silva Campos Bragagnoli, Marina Nechaeva, Min Hee Ryu, Huiling Xiong, Toshimi Takano, Sara Lonardi, Narikazu Boku, Mustafa Ozguroglu, Howard Safran, Alina Muntean, Rachel Wong, Mikhail Dvorkin, Antonio Cubillo Gracian, Hasan Şenol Coşkun
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol 39, iss 9
PURPOSE The role of maintenance therapy for gastric (GC) or gastroesophageal junction cancer (GEJC) is unclear. We investigated avelumab (anti–programmed death ligand-1 [PD-L1]) maintenance after first-line induction chemotherapy for GC/GEJC. PATIE
Autor:
Megan Othus, Roland B. Walter, Raffaele Palmieri, Pamela S. Becker, Anna B. Halpern, Colin D. Godwin, Mary-Elizabeth M. Percival
Publikováno v:
J Clin Oncol
PURPOSE With increasing therapeutic alternatives available, there is growing interest in tools that accurately identify patients most suitable for intensive acute myeloid leukemia (AML) chemotherapy. Nowadays, conceptual criteria proposed by an Itali
Autor:
Hélène Senellart, Sung Bae Kim, Takashi Kojima, Antoine Adenis, Shukui Qin, Peter C. Enzinger, Jaafar Bennouna, Jia Chen, Toshihiko Doi, Jean-Philippe Metges, Ken Kato, Lin Shen, Christelle De La Fouchardiere, Kei Muro, Eric Francois, Toshikazu Moriwaki, Keynote Investigators, S. Peter Kang, Shailaja Suryawanshi, Se-Hoon Lee, Ruixue Wang, Raed Al-Rajabi, Florian Lordick, Paula Ferreira, Gustavo Girotto, Chih-Hung Hsu, Manish A. Shah, Pooja Bhagia
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 38(35)
PURPOSE Patients with advanced esophageal cancer have a poor prognosis and limited treatment options after first-line chemotherapy. PATIENTS AND METHODS In this open-label, phase III study, we randomly assigned (1:1) 628 patients with advanced/metast
Autor:
Masahiro Kashiwaba, Tsuyoshi Saito, Michiko Tsuneizumi, Hiroji Iwata, Noriko Sagawa, Hiroaki Kawashima, Takuya Kawahara, Miki Yamaguchi, Yasuo Ohashi, Tsutomu Takashima, Masataka Sawaki, Toshiro Mizuno, Naruto Taira, Shinichi Baba, Yutaka Yamamoto, Hirofumi Mukai, Yukari Uemura, Takahiro Nakayama, Hiroko Bando, Masato Takahashi, Kokoro Kobayashi
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 38(32)
PURPOSE Adjuvant trastuzumab monotherapy has not been compared with trastuzumab + chemotherapy. We investigated the relative value of trastuzumab monotherapy for older patients with breast cancer. METHODS This study was an open-label, randomized cont
Autor:
Steven P. Treon, Christopher J. Patterson, Guang Yang, Jacob P. Laubach, Zachary R. Hunter, Andrew R. Branagan, Xia Liu, Irene M. Ghobrial, Kirsten Meid, Jorge J. Castillo, Lian Xu, Ranjana H. Advani, M. Lia Palomba, Joshua Gustine
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 39(6)
PURPOSE We report the long-term findings and final analysis of a pivotal multicenter trial of ibrutinib monotherapy in previously treated patients with Waldenström macroglobulinemia (WM). PATIENTS AND METHODS Sixty-three symptomatic patients with me
Autor:
Ragini R. Kudchadkar, Uwe M. Martens, Paul Nghiem, Robert L. Ferris, Julie E. Stein, Junchen Gu, Suzanne L. Topalian, Michi M. Shinohara, Adam Barrows, Christine H. Chung, Rima M. Kulikauskas, Jean Pierre Delord, Lara Dunn, Andrea Horvath, Janis M. Taube, Shailender Bhatia, Lot A. Devriese, William H. Sharfman, Bin Li, Céleste Lebbé, Tian Chen, Asim Amin, Elizabeth L. Engle, Christopher D. Lao
Publikováno v:
J Clin Oncol
PURPOSE Merkel cell carcinoma (MCC) is a rare, aggressive skin cancer commonly driven by the Merkel cell polyomavirus (MCPyV). The programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) immunosuppressive pathway is often upregulated in MCC, and